Gland Pharma Q4 FY26 Earnings Call Transcript Released
Gland Pharma released its Q4 FY26 earnings call transcript. Q4 FY26 revenues grew 22% YoY to ₹17,428 million. Full year FY26 revenues increased 14.5% to ₹64,307 million. The CDMO segment saw 28% growth, contributing 46% of total revenues. Cenexi achieved EBITDA positive status. Capex of ₹2,000 crore planned over five years.
The announcement is a transcript of an earnings call, which provides detailed financial performance and strategic updates. While positive, it primarily confirms previously announced financial results and outlook, making the impact medium rather than high.
The company reported strong year-on-year growth in revenues and profitability for Q4 FY26 and the full year. Positive performance across segments, including the turnaround of Cenexi and growth in the CDMO business, indicates a favorable outlook.
Gland Pharma Limited has released the transcript of its Earnings Call for the fourth quarter of Fiscal Year 2026 (Q4 FY26), which was held on Friday, May 15, 2026, at 18:30 IST. The transcript is available on the company's website.
During the call, the management reported a strong Q4 FY26 performance with consolidated revenues of ₹17,428 million, marking a 22% year-on-year growth. Adjusted EBITDA stood at ₹5,244 million (30% margin), and adjusted profit after tax was ₹3,667 million (21% margin). For the full year FY26, consolidated revenue grew by 14.5% to ₹64,307 million, with Adjusted EBITDA at ₹16,826 million (26% margin) and adjusted PAT at ₹10,455 million (16% margin).
The company highlighted robust growth in the CDMO segment, which contributed 46% of total revenues with a 28% growth. The US market remained the largest, with Q4 revenues at ₹9,716 million (up 26% YoY). Europe and other regulated markets saw Q4 revenues of ₹794 million, while rest of the world markets reported ₹1,468 million (up 17% YoY).
Cenexi business demonstrated steady performance with Q4 revenues of EUR45 million (up 4% YoY) and achieved EBITDA positive status. For the full year FY26, Cenexi revenues were EUR182 million (up 11% YoY).
The company plans significant capacity expansions with a capex outlay of ₹2,000 crores over the next five years. R&D expenses for FY26 were ₹2,230 million (5% of base business revenue), with 24 ANDAs filed and 28 approvals received in the US.
Management expressed confidence in sustaining momentum through new product launches, CDMO partnerships, and cost efficiency initiatives, expecting continued strong EBITDA margins.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.